KAS
XFOR icon

Kestra Advisory Services’s X4 Pharmaceuticals XFOR Stock Holding History

Kestra Advisory Services’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,100
Closed -$56K – 2351
2022
Q3 		$56K Hold
1,100
– – ﹤0.01% 2022
2022
Q2 		$32K Buy
+1,100
New +$41.8K ﹤0.01% 2071

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
TLP
Tri Locum Partners New York $713M AUM 68.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $970M AUM 79.46% 1-Year Est. Return
LCM
Lynwood Capital Management Toronto, Ontario, Canada $16.9M AUM 19.31% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

Kestra Advisory Services's XFOR Position: Q4 2022 in Review

Kestra Advisory Services sold out of X4 Pharmaceuticals (XFOR) in Q4 2022, closing a stake of 1,100 shares — an estimated $56K sold.

Kestra Advisory Services first reported a position in XFOR in Q2 2022 and held it in 2 quarters. The position peaked at $56K in Q3 2022. 52 funds tracked by Wall St. Rank hold XFOR as of Q4 2022.

  • Kestra Advisory Services reported no remaining X4 Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Kestra Advisory Services sold 1,100 X4 Pharmaceuticals shares in Q4 2022, an estimated $56K.
  • Kestra Advisory Services first reported a position in X4 Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Kestra Advisory Services's X4 Pharmaceuticals position peaked at $56K in Q3 2022.
  • 52 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2022.

Based on Kestra Advisory Services's 13F filing for Q4 2022, filed 31 Jan 2023.